Regulator
China's regulator, the NMPA, approved Toumai SP, a single-port version, for urology, general surgery and gynecology.
A regulator's decision · Company-reported · Sets Toumai's stage
What the source says
“Toumai SP laparoscopic surgical robot has received National Medical Products Administration approval in China.”
What it means
Toumai, from MicroPort MedBot (MicroPort group), is at stage 5 of 5 on our ladder: regulator-cleared or mass market. This event is one of the milestones that placed it there. This line rests on the company's own announcement; no regulator, customer or independent report confirms it in our sources yet.
Human help: Our sources report it working without human help.
More on Toumai
- MicroPort MedBot, Toumai's maker, said it expected its first-ever half-year profit, of about 28 to 40 million yuan.
- A surgeon used Toumai to do ten remote weight-loss operations in one session of about 11 hours, linking IRCAD sites in Strasbourg, France and Indore, India.
- MicroPort signed a cooperation agreement built around Toumai with Korea University Anam Hospital in South Korea.
- Toumai received a CE mark in the European Union for remote surgery in urology, general surgery, chest surgery and gynecology.
- Surgeons did six prostate cancer operations with Toumai in Angola, two of them remotely from another site on the same hospital campus. MicroPort said Toumai had been used in more than 200 remote operations worldwide.